{"schema_version":"1","generated_at":"2026-11-21T17:30:57.777Z","data_as_of":null,"url":"https://www.findmykol.com/kol/christopher-yasenchak","json_url":"https://www.findmykol.com/kol/christopher-yasenchak/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"christopher-yasenchak","name":"Christopher Yasenchak","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Willamette Valley Cancer Institute and Research Center","institution_url":"https://www.findmykol.com/institution/willamette-valley-cancer-institute-and-research-center","city":"Eugene","state":"OR","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Christopher Yasenchak is an Oncology physician affiliated with Willamette Valley Cancer Institute and Research Center. OpenAlex indexes 103 publications with 1,306 citations (h-index 16).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":103,"cited_by_count":1306,"h_index":16,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":12,"program_years":{"first":2021,"last":null},"rows_total":49,"shown":3,"withheld":46,"rows":[{"payer":"Bristol Myers Squibb","program_year":2025,"amount_usd":64443.17,"payment_count":5},{"payer":"Takeda","program_year":2025,"amount_usd":33277.07,"payment_count":7},{"payer":"Sanofi","program_year":2025,"amount_usd":28500,"payment_count":3}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":9,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":46.3,"classes_total":3,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":24,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":12},{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":22.2,"drugs":[{"name":"Darbepoetin alfa","share_pct":100}],"max_beneficiaries":11}]},{"area":"Cancer & immunology","share_pct":36.2,"classes_total":11,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":28.1,"drugs":[{"name":"Pembrolizumab","share_pct":52.8},{"name":"Nivolumab","share_pct":47.2}],"max_beneficiaries":14},{"class":"Microtubule Inhibitor","setting":"administered","share_pct":6.7,"drugs":[{"name":"Paclitaxel","share_pct":100}],"max_beneficiaries":11}]},{"area":"Metabolism & gastrointestinal","share_pct":14.3,"classes_total":5,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":11.6,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":21},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":2.5,"drugs":[{"name":"Palonosetron hcl","share_pct":55.4},{"name":"Granisetron hydrochloride","share_pct":39.7},{"name":"Ondansetron Hcl","share_pct":5}],"max_beneficiaries":34}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.9,"facility_pct":0.1},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-24-02242","status":"verified"},{"title":"Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025030190","status":"verified"},{"title":"Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma","year":2025,"journal":"Future Oncology","source_url":"https://doi.org/10.1080/14796694.2025.2513219","status":"verified"},{"title":"Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.7040","status":"verified"},{"title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","year":2024,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2024024681","status":"verified"}],"source":"works"},"similar":[{"name":"Jeff Sharman","slug":"jeff-sharman","institution":"Willamette Valley Cancer Institute and Research Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jeff-sharman","json_url":"https://www.findmykol.com/kol/jeff-sharman/profile.json"},{"name":"James Butrynski","slug":"james-butrynski","institution":"Willamette Valley Cancer Institute and Research Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/james-butrynski","json_url":"https://www.findmykol.com/kol/james-butrynski/profile.json"},{"name":"Merideth Wendland","slug":"merideth-wendland","institution":"Willamette Valley Cancer Institute and Research Center","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/merideth-wendland","json_url":"https://www.findmykol.com/kol/merideth-wendland/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":46,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}